Literature DB >> 12808533

Overwork weakness in Charcot-Marie-Tooth disease.

Paolo Vinci1, Carolina Esposito, Sandra L Perelli, Jo Ann V Antenor, Florian P Thomas.   

Abstract

OBJECTIVE: To determine the incidence of overwork weakness in Charcot-Marie-Tooth disease (CMT).
DESIGN: Prospective survey.
SETTING: Rehabilitation department for CMT in an Italian tertiary care hospital. PARTICIPANTS: A total of 106 outpatients with CMT, selected for absence of other causes of weakness (age range, 11-69y), and 48 healthy volunteers (controls).
INTERVENTIONS: The strength of 2 intrinsic hand muscles (abductor pollicis brevis [APB], first dorsal interosseous) in the dominant and nondominant hands was graded by using manual muscle testing and a modified Medical Research Council (MRC) Scale. MAIN OUTCOME MEASURES: The side of the stronger muscle and the difference in strength between the nondominant and dominant muscles.
RESULTS: Muscles were stronger on the nondominant side in 65.57% of patients versus 1.04% of controls, and on the dominant side in .94% of patients versus 84.38% controls. The difference in strength for first dorsal interosseous was .51 in patients and -.32 in controls (P>.01). The difference in strength for APB was .65 in patients and -.35 in controls (P>.01).
CONCLUSIONS: CMT muscles in the dominant hand are weaker than in the nondominant hand. This may be the result of overwork weakness.

Entities:  

Mesh:

Year:  2003        PMID: 12808533     DOI: 10.1016/s0003-9993(02)04949-3

Source DB:  PubMed          Journal:  Arch Phys Med Rehabil        ISSN: 0003-9993            Impact factor:   3.966


  9 in total

1.  Current Therapy for Charcot-Marie-Tooth Disease.

Authors:  Marina Grandis; Michael E Shy
Journal:  Curr Treat Options Neurol       Date:  2005-01       Impact factor: 3.598

2.  Functional results and quality of life after joint preserving or sacrificing surgery in Charcot-Marie-Tooth foot deformities.

Authors:  Sergio Tejero; Juan Chans-Veres; Andrés Carranza-Bencano; Ahmed E Galhoum; Daniel Poggio; Victor Valderrábano; Mario Herrera-Pérez
Journal:  Int Orthop       Date:  2021-02-21       Impact factor: 3.075

3.  The Bournemouth Questionnaire as an outcome measure in the rehabilitation of a person suffering with mechanical neck and arm pain and concurrent Charcot-Marie-Tooth disease: a case report.

Authors:  Paul Rankin
Journal:  J Can Chiropr Assoc       Date:  2006-09

4.  Inherited neuropathies.

Authors:  Angelo Schenone; Lucilla Nobbio; Margherita Monti Bragadin; Giulia Ursino; Marina Grandis
Journal:  Curr Treat Options Neurol       Date:  2011-04       Impact factor: 3.598

5.  Hand weakness in Charcot-Marie-Tooth disease 1X.

Authors:  P J Arthur-Farraj; S M Murphy; M Laura; M P Lunn; H Manji; J Blake; G Ramdharry; Z Fox; M M Reilly
Journal:  Neuromuscul Disord       Date:  2012-03-28       Impact factor: 4.296

Review 6.  Management of Charcot-Marie-Tooth disease: improving long-term care with a multidisciplinary approach.

Authors:  Donald McCorquodale; Evan M Pucillo; Nicholas E Johnson
Journal:  J Multidiscip Healthc       Date:  2016-01-19

7.  Treadmill training in patients affected by Charcot-Marie-Tooth neuropathy: results of a multicenter, prospective, randomized, single-blind, controlled study.

Authors:  L Mori; A Signori; V Prada; D Pareyson; G Piscosquito; L Padua; C Pazzaglia; G M Fabrizi; A Picelli; A Schenone
Journal:  Eur J Neurol       Date:  2019-09-25       Impact factor: 6.089

Review 8.  The genetics of Charcot-Marie-Tooth disease: current trends and future implications for diagnosis and management.

Authors:  J Chad Hoyle; Michael C Isfort; Jennifer Roggenbuck; W David Arnold
Journal:  Appl Clin Genet       Date:  2015-10-19

9.  The suspected SARS-Cov-2 infection in a Charcot-Marie-Tooth patient undergoing postsurgical rehabilitation: the value of telerehabilitation for evaluation and continuing treatment.

Authors:  Valeria Prada; Emilia Bellone; Angelo Schenone; Marina Grandis
Journal:  Int J Rehabil Res       Date:  2020-09       Impact factor: 1.832

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.